This pathway is particularly interesting since the expression of CD99 in T cells is sought to detect minimal residual disease in acute lymphoblastic leukemia [80]; and some clinical trials propose CD99 as a therapeutic target in AML [52,100]. The gene discussed is CD99; the disease is acute lymphoblastic leukemia.